Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23552012 | 0.88 | PPARG (0.51) | PPARGPPARDPPARAHTR2AHTR2C | |
| SCHEMBL23015424 | 0.86 | HTR2A (0.53) | PPARGPPARDPPARAHTR2AHTR2C | |
| SCHEMBL23257472 | 0.86 | HTR2A (0.53) | PPARGPPARDPPARAHTR2AHTR2C | |
| SCHEMBL23552072 | 0.86 | HTR2A (0.54) | PPARGPPARDPPARAHTR2AHTR2C | |
| SCHEMBL22231523 | 0.86 | PPARG (0.72) | PPARGPPARDPPARAHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL23525207 | 0.85 | HTR2A (0.52) | PPARGPPARDPPARAHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL23525210 | 0.85 | HTR2A (0.52) | PPARGPPARDPPARAHTR2AHTR2C | |
| SCHEMBL15446164 | 0.83 | PPARG (0.54) | PPARGPPARDPPARAHTR2AHTR2C | |
| SCHEMBL22231349 | 0.83 | PPARG (0.74) | PPARGPPARDPPARAHTR2AHTR2C | |
| SCHEMBL237566 | 0.83 | HTR2A (0.57) | PPARGPPARDPPARAHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397358-A1 | TROPANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002102801-A1 | TROPANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2002-12-27 | — | — | WO | disclosed |
| US-20020128284-A1 | Tropane-derivatives, their preparation and use | NEUROSEARCH A/S | 2002-09-12 | — | — | US | disclosed |
| EP-0756596-B1 | TROPANE-2-ALDOXIME DERIVATIVES AS NEUROTRANSMITTER REUPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2002-08-21 | — | — | EP | disclosed |
| US-6288079-B1 | MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS; NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, SLEEP, AND BRAIN DISORDERS; ALZHEIMER*S AND PARKINSON*S DISEASE; TESOFENSINE (2-ethoxymethyl-3-(3,4-dichlorophenyl)-tropane) | NEUROSEARCH A/S (DK) | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128284-A1 | Tropane-derivatives, their preparation and use | ADRB3, ADRB2, ADRA2C | PPARG 3479/4885PPARD 2832/4885PPARA 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.